Plain-English translation of NCT07038720 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a first-in-human trial of , a new oral medication designed to reduce inflammation in the body by blocking a protein called IL-17A. The study will check whether the medication is safe and how the body processes it in both healthy volunteers and people living with moderate to severe plaque psoriasis. Researchers will also measure how well the treatment works by checking blood markers and skin improvement.
Plaque psoriasis is caused by excessive inflammation in the skin, driven partly by a protein called IL-17A. Blocking this protein has helped other patients significantly, and this medication may offer a new, easier-to-use treatment option for people who don't respond well to or can't tolerate current therapies.
You likely qualify if…
You likely don't qualify if…
Participants will visit the research center multiple times over several weeks or months. Healthy volunteers will receive either a single dose or multiple doses of the medication (or placebo) and have blood drawn regularly to monitor safety and how the body processes the drug—some will also take the medication with food to see if that affects absorption. People with psoriasis will take multiple doses of the medication over time while researchers track safety, tolerability, and improvement in skin symptoms through lab tests and skin assessments.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China